Navigation Links
Cancer Cure Coalition Proposes Major Changes at the FDA
Date:2/21/2008

fety, regulators keep raising the bar for approval, especially for innovative, high-tech products."

We at the Cancer Cure Coalition agree with Dr. Miller that "What the FDA needs is competent management, discipline in the ranks, more effective risk- benefit balancing, a commitment to permitting patients to assume more responsibility for the risk of medicines, and the banishment of politics from regulatory decisions and policy."

We think that reform is needed as soon as possible, and we propose the following steps be taken:

1. Substantial additional funding should be given to the FDA to help it fulfill the increase in duties placed upon it by the Congress.

2. The "Food" division should be separated from the "Drug" division. Insuring the safety of food for the United States is an enormous responsibility and would be best performed by an agency dedicated to that purpose.

3. A special study should be made by an independent organization to make sure that the FDA has competent management. Those managers who are incompetent should be replaced. In the "Drug" division, management is needed that will recognize the needs of the patients and that will apply effective risk-benefit balancing.

4. Consideration should be given to using certified non-governmental agencies to perform the oversight of drug testing and the review of new drug applications. This would reduce cost while improving the quality of the review process.

Unless we move for reform now, the FDA will continue to harm the interests of patients, our health industry and the economy of the United States.

Contact:

Charles A. Reinwald, Chairman

Charles Reinwald, Jr., President

Cancer Cure Coalition

561-747-2174

E-mail: cancercurecoal@aol.com

http://www.cancercurecoalition.org

This release was issued through eRele
'/>"/>

SOURCE Cancer Cure Coalition
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. Diagnostic Center for Disease: Prostate Biopsy Spreads Prostate Cancer Cells
4. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
5. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
8. Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
9. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
10. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
11. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015 AVT, Inc. (OTC Markets: AVTC) ... systems, announced today that their customer, Pharmabox, has introduced ... self-service kiosk carries over 140 top selling brand name ... Walgreen,s or Rite Aid-type store. As ... Miami -based Pharmabox worked with AVT ...
(Date:6/3/2015)... DIEGO , June 3, 2015  Halozyme ... a global collaboration and license agreement with AbbVie ... combining proprietary AbbVie compounds with Halozyme,s ENHANZE ™ ... of the agreement, Halozyme will receive an initial ... approximately $130 million for each of up to ...
(Date:6/3/2015)... 3, 2015 According to ... Peripheral Vascular Devices Market (Embolic Protection, Chronic Total ... Grafts, IVC Filters, Stents, Balloons and Accessories) - ... Cardiology and Peripheral Vascular Devices Market is expected ... a CAGR of 7.4% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmabox Introduces New Concept with a Boldly Designed Automated Retailing System 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4
... Inc. (NYSE: VRX ) (TSX: VRX) today announced ... Internet webcast along with a slide presentation on Thursday, February ... discuss results for the 2010 fourth quarter and full year. ... is (877) 295-5743, confirmation code 41335702.  International callers should dial ...
... PARK, Calif., Feb. 15, 2011 ForteBio®, Inc., a ... of biotherapeutic and pharmaceutical products, today announced the launch ... new Dip and Read Protein L Biosensor for use ... widen the scope and utility of the company,s flagship ...
Cached Medicine Technology:Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2ForteBio Launches New Octet® RED96 System and Dip and Read™ Protein L Biosensor 2
(Date:6/3/2015)... A group of nine authors involved with ... Inspire Award at DIA’s upcoming Annual Meeting. DIA’s Global ... their leadership, level of excellence, and commitment to service ... of the Author(s) of the Year Award, which acknowledges ... made a significant impact in advancing medical product development, ...
(Date:6/3/2015)... 03, 2015 Z-Medica®, LLC, a leading ... June has been designated as National Safety Month by ... AZ. Police Department for its commitment to public safety. ... their Individual First Aid Kits (IFAK) over 100 times ... shootings, stabbings or traffic accidents. Each kit is equipped ...
(Date:6/3/2015)... June 03, 2015 Researchers at the ... for mesothelioma and say the tried-and-true marker mesothelin is ... an article on the research. Click here to ... National Center for Asbestos Related Diseases say, even though ... it is still preferable to fibulin-3 for identifying mesothelioma. ...
(Date:6/3/2015)... According to an article published on May14th by ... pills which actually contained the potent addictive drug fentanyl. ... even sported the “A/215” imprint common on real oxycodone ... oxycodone to be exceptionally critical of their prescriptions—especially those ... on the street. Fentanyl is an opiate-based narcotic and ...
(Date:6/3/2015)... Atlanta, GA (PRWEB) June 03, 2015 ... A in Duluth, GA will celebrate its grand opening ... 2015. , The first prosthetic center of its kind ... and their family unmatched care and outcomes through use ... Keith Watson, CPO & CEO of Fourroux Prosthetics, states, ...
Breaking Medicine News(10 mins):Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2
... , , WASHINGTON, July 22 There ... (H.R. 3200) that concern citizens who care greatly about the freedom to ... bill: , , * Eliminates Existing Private ... "Acceptable" to the Federal Government, But Is Just Fine With You ...
... , , , ... consecutive year, Regence won four bronze (second-place) Telly Awards for originally created ... Web site for Regence members. , , ... of non-news and advertising video production; Regence,s videos were selected from more ...
... , SAN DIEGO, July 22 ... it intends to offer, subject to market and other conditions, 9,000,000 ... connection with this offering, Orexigen expects to grant to the underwriter ... of common stock to cover overallotments, if any. All of the ...
... , LANCASTER, Pa., July 22 The Board of Directors for Herley ... management leadership. , , , ... Lieberman named Chairman of The Board , Richard Poirier ... Walker (Ret.) to continue as Vice Chairman of the Board , ...
... Finding may lead to new treatments, researcher says , WEDNESDAY, ... thrombomodulin, which is involved in blood clotting and preventing cell ... new Canadian study suggests. , The finding might lead to ... about 300 children affected by it in the United States, ...
... such program in world started in Australia , WEDNESDAY, ... readying its first human trials of an experimental vaccine ... announced Wednesday. , Two possible vaccines will be tested ... of the National Institute of Allergy and Infectious Diseases ...
Cached Medicine News:Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2Health News:Regence Wins Four Telly Awards for Health and Wellness Videos 2Health News:Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock 2Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 2Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 3Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 4Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 5Health News:Gene Mutation Could Be Key to Rare Blood Vessel Disease 2Health News:Gene Mutation Could Be Key to Rare Blood Vessel Disease 3Health News:U.S. Swine Flu Vaccine Trials Set to Begin 2Health News:U.S. Swine Flu Vaccine Trials Set to Begin 3Health News:U.S. Swine Flu Vaccine Trials Set to Begin 4Health News:U.S. Swine Flu Vaccine Trials Set to Begin 5Health News:U.S. Swine Flu Vaccine Trials Set to Begin 6Health News:U.S. Swine Flu Vaccine Trials Set to Begin 7Health News:U.S. Swine Flu Vaccine Trials Set to Begin 8Health News:U.S. Swine Flu Vaccine Trials Set to Begin 9Health News:U.S. Swine Flu Vaccine Trials Set to Begin 10Health News:U.S. Swine Flu Vaccine Trials Set to Begin 11Health News:U.S. Swine Flu Vaccine Trials Set to Begin 12Health News:U.S. Swine Flu Vaccine Trials Set to Begin 13
... product solutions were developed to assist in ... To maximize use of existing capital equipment, ... the productivity of their employees, organizations are ... their valuable assets and ensure those assets ...
... Mobile Location-ID™ offers a for asset tracking electronically. ... to all the assets that will be tracked. ... equipped with a reader, antenna, and a portable ... small as 10 inches x 6 inches. One ...
Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
... provides hospitals with a suite ... all their supplies, drugs, assets, ... remove all manual compliance from ... accurately. iRIS, or Intelligent Radio-Frequency ...
Medicine Products: